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Abstract
Background: Bipolar Disorder (BD) is a mental disorder usually diagnosed between 18 and 30 years of age; this
coincides with the period when many women experience pregnancy and childbirth. As specific problems have
been reported in pregnancy and childbirth when the mother has BD, a systematic review was carried out to
summarise the outcomes of pregnancy and childbirth, in mother and child, when the mother has BD diagnosed
before pregnancy.
Methods: An a priori protocol was designed and a systematic search conducted in PubMed, CINAHL, Scopus,
PsycINFO and Cochrane databases in March 2015. Studies of all designs were included if they involved women with a
diagnosis of bipolar disorder prior to pregnancy, who were pregnant and/or followed up to one year postpartum. All
stages of inclusion, quality assessment and data extraction were done by two people. All maternal or infant outcomes
were examined, and narrative synthesis was used for most outcomes. Meta-analysis was used to achieve a combined
prevalence for some outcomes and, where possible, case and control groups were combined and compared.
Results: The search identified 2809 papers. After screening and quality assessement (using the EPHPP and AMSTAR
tools), nine papers were included. Adverse pregnancy outcomes such as gestational hypertension and antepartum
haemorrhage occur more frequently in women with BD. They also have increased rates of induction of labour and
caesarean section, and have an increased risk of mood disorders in the postnatal period. Women with BD are more
likely to have babies that are severely small for gestational age (<2nd-3rd percentile), and it appears that those women
not being treated with mood stabilisers in pregnancy might not have an increased risk of having a baby with
congenital abnormalities.
Discussion: Due to heterogeneity of data, particularly the use of differing definitions of bipolar disorder,
narrative synthesis was used for most outcomes, rather than a meta-analysis.
Conclusions: It is evident that adverse outcomes are more common in women with BD and their babies.
Large cohort studies examining fetal abnormality outcomes for women with BD who are not on mood
stabilisers in pregnancy are required, as are studies on maternal-infant interaction.
Keywords: Bipolar disorder, Affective disorders, Mania, Pregnancy, Postpartum, Delivery, Parturition, Childbirth
Background
Bipolar Disorder (BD) is a severe affective mood dis-
order characterized by a wide range of lifelong mood
changes varying between depressive, hypomanic, manic
or mixed episodes [1, 2]. The lifetime prevalence for the
most common variations within the BD spectrum, BD-I
and BD-II, is reported as 1–2.4 % [3, 4]. A recent study
from Sweden reports that incidence and prevalence of
BD has increased during the last 20 years [5]. BD entails
a significant burden for those that are affected as well as
high societal costs related to health care, sick leave and
early retirement [6]. The Swedish study has found that
in persons with BD, despite similar education levels, em-
ployment levels are lower and disposable income is less
compared to the general population. Also, persons with
BD have more sick leave compared to the general popu-
lation [5]. BD is a severe condition, and an example of
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this is that the suicide risk in people with this disorder is
about 20–30 times greater than that for the general
population [7].
The time when many women experience pregnancy,
childbirth and early postpartum overlaps the period be-
tween 18 and 30 years when most women are diagnosed
with BD [8]. Being pregnant and giving birth to a child
is a key life transition event comprising engagement,
growth and transformation [9]. Women with mental
illness, however, often experience problems and in-
creased risk of complications related to childbearing
[10]. Female patients with psychiatric disorders seem to
have more negative attributes with regard to sexuality
and reproduction [11]. The complex picture of problems
that women with BD face include: sexually risky behav-
iour during episodes of mania, health related risks for
the mother and/or the baby, decisions regarding medica-
tion during pregnancy, as well as decisions related to
unplanned/undesired pregnancy, and sexually transmit-
ted infections [12–16].
As a basis for developing high quality healthcare
with best health outcomes for mother and child when
the pregnant woman has BD, there is need for a sci-
entific overview of the risks. The aim of this paper is,
through a systematic literature review, to summarise
outcomes of pregnancy and childbirth, in mother and
child, when the mother has bipolar disorder diag-
nosed before pregnancy.
Methods
The research question guiding this systematic review
was: What are the outcomes of pregnancy and childbirth
(childbirth defined as labour and birth, and the first year
postpartum) for women with bipolar disorder and their
fetus/infant, when compared with outcomes for women
with bipolar disorder, who are not pregnant, experien-
cing labour and birth, or postnatal. We were open to all
scientific findings in the field.
Search strategy
The use of the accepted definition of bipolar disorder
[1, 2] was planned. An a priori protocol was
designed, outlining the aim and procedure for the
review and is available in the Additional file 1. An in-
clusion/exclusion criteria list was developed from
identifying relevant PICOS (Table 1), and then tested
with the PRESS criteria [17], to guide inclusion of all
relevant studies. A comprehensive and systematic
search was done in the following databases: PubMed,
CINAHL, Scopus, PsycINFO and Cochrane, from in-
ception until 10th of March 2015, to identify studies
or existing systematic reviews. The final search string
for PubMed is available in the Additional file 1,
Table 2. A repeat search in PubMed and Cochrane
Library was conducted in March 2016 to check for
any new papers that should be included in the discus-
sion section, for comparison.
We limited our search to peer-reviewed papers. We
planned to include randomised trials if the control groups
could provide outcomes due to BD, but none were found.
A total of 2809 papers were found in the five databases
(PubMed n = 877, CINAHL n = 240, PsychINFO n = 512,
Scopus n = 1156 and Cochrane n = 24). After deletion of
duplicates by two reviewers (MR, MB), 1700 papers
remained. Exclusion of papers by title and abstract was
made by two reviewers (MR, MB) based on assessment
of the inclusion and exclusion criteria. In case of dis-
agreement the third reviewer (CB) was involved. This
process ended in exclusion of 1652 papers. The full text
of the remaining papers (n = 48) was read by three teams
of two researchers each (MR/MB, MR/CB, MB/CB). Five
further studies were added from their reference lists.
Of these 53, 35 papers were excluded (Fig. 1).
Reasons for exclusion were: drug related issues (21
papers, [14, 18–37]), no focus on the chosen study
group (six papers, [38–43]), outcomes in women not
diagnosed before pregnancy (two papers, [44, 45]), mixed
groups bipolar disorder and schizophrenia (two papers,
[46, 47]), discussion paper (two papers, [48, 49]), gender
mixed groups also including men (one paper, [50]), dupli-
cates (one paper, [15]). Occasionally it was difficult to
separate the different diagnoses that were included in the
sample; for example, in Doyle et al. [46] it was not possible
to find separate data for the three included groups: BD I,
BD II and schizoaffective disorders bipolar type. In Mac
Cabe et al. [47] it was difficult to determine whether
women with additional diagnoses were included in the
sample or not, so both these papers were excluded. Eight-
een papers (15 studies and 3 reviews) were thus quality
assessed by the three pairs.
A repeat search in PubMed and Cochrane Library was
conducted in March 2016, using the same methodology,
to check for any new papers that should be included in
the discussion section, for comparison. Fifty-eight papers
were found in PubMed in this second search and no pa-
pers in the Cochrane Library. Four new papers [51–54]
were found to be topical for this review. Logsdon et al.
2015 [51] described maternal-infant interaction at
12 months postpartum in women with BD compared to
women with unipolar depression and a control group
without a major mood disorder. Marengo et al. 2015
[52] looked at how women with BD made reproductive
decisions. Both of these papers are included in the dis-
cussion section only, for noting, as they were published
too late to be included in the review. Taylor et al. 2015
[53] was excluded, as their description of the character-
istics of pregnant women and their use of psychotropic
medication was not relevant for this review. The fourth
Rusner et al. BMC Pregnancy and Childbirth  (2016) 16:331 Page 2 of 18
paper, a review and meta-analysis by Wesseloo et al.
2016 [54] was also not relevant for inclusion as it in-
cluded women who had a psychotic or manic episode
following childbirth, even if they had never had a diag-
nosis of BD in pregnancy.
Quality assessment
To assess the studies for quality the validated Effective
Public Health Practice Project (EPHPP) tool [55] was
used for original studies (n = 15), based on six categories
including study design, selection bias and data collection
methods. Each item was given a rating of strong, moder-
ate or weak, based on how well the criteria were met.
An overall strong, moderate or weak rating was awarded
for studies with no, one, or two or more “weak” categor-
ies. We excluded six studies rated as “weak” [56–61].
The quality of the reviews (n = 3) was assessed using the
AMSTAR tool [62, 63]. Each of the eleven issues is rated
with Yes, No, Can’t answer or Not Applicable. Every yes
is given one mark; 8 to 11 marks is “high quality”, 4 to 7
is “medium”, and 0 to 3 is “low quality”. We excluded all
three reviews due to “low quality” [64–66].
The 9 remaining papers were included, 4 of which had
a “strong” rating, and 5 a “moderate” (Table 3).
Data extraction and analysis
Three teams of two reviewers extracted key findings
from each study, as well as potential explanations given
by the authors for results, and their recommendations,
using a pre-designed data collection form. Any disagree-
ments were resolved by consensus. Meta-analysis was
not always possible because of heterogeneity in the ma-
jority of studies (due to differing definitions of BD, or
non-similar cohorts), so a descriptive narrative synthesis
was used for most outcomes. When appropriate (similar
definitions of BD), simple meta-analysis was used to
achieve a combined prevalence. In a few cases, we were
able to combine and compare case and control groups,
when similar methods had also been used in two or
more studies. Odds ratios were computed using
MedCalc online statistical software (https://www.med
calc.org/download.php) and heterogeneity between stud-
ies was calculated using RevMan, the Cochrane Collab-
oration software (Review Manager, 2014). The study by
Jablensky et al. [67] had a mixed cohort that included
only 55 % of women with pre-existing BD, so has been
left out of all meta-analyses performed.
Results
In the following pages we describe the identified out-
comes of pregnancy and childbirth in mothers, and their
children, when the mother has BD diagnosed before
pregnancy.
Description of included studies
Characteristics of the nine included studies are pre-
sented in Table 3. Outcome data measured were risks or
complications for the pregnancy, mother, fetus and/or
baby. Seven of the nine papers had a retrospective
Table 1 PICOS and Key words
PICOS Key words
Population: Women with established diagnosis of bipolar disorder prior
to pregnancy
Bipolar disorder OR affective disorders, psychotic OR affective
psychosis OR mania
Intervention/Exposure: Pregnancy, labour and birth, and the first year
post-partum
Pregnancy OR postpartum period OR delivery, obstetric OR
parturition OR abortion, spontaneous OR abortion, induced
OR childbirth
Comparison: Women with bipolar disorder, not experiencing pregnancy
or childbirth
Women with bipolar disorder, not experiencing childbirth
Outcome: All maternal or infant health outcomes. Papers that compared
effects of using different pharmaceutical treatments were excluded.
The terms ‘woman, fetus, neonate and infant’
Study design: Qualitative studies, Meta-syntheses, Surveys, Cross-sectional
studies, Case reports, Experimental studies (RCTs), Quasi-experimental studies,
Observational studies, Systematic reviews, Meta-analyses
Qualitative, Meta-syntheses, Surveys, Cross-sectional, Case reports,
Experimental, Randomised controlled trials, Quasi-experimental,
Observational, Systematic reviews, Meta-analyses
Table 2 Final search string for PubMed
Bipolar disorder AND (pregnancy OR postpartum period OR delivery,
obstetric OR parturition OR abortion, spontaneous OR abortion, induced)
(“bipolar disorder”[MeSH Terms] OR (“bipolar”[All Fields] AND
“disorder”[All Fields]) OR “bipolar disorder”[All Fields]) AND
((“pregnancy”[MeSH Terms] OR “pregnancy”[All Fields]) OR (“postpartum
period”[MeSH Terms] OR (“postpartum”[All Fields] AND “period”
[All Fields]) OR “postpartum period”[All Fields]) OR (“delivery, obstetric”
[MeSH Terms] OR (“delivery”[All Fields] AND “obstetric”[All Fields]) OR
“obstetric delivery”[All Fields] OR (“delivery”[All Fields] AND”obstetric”
[All Fields]) OR “delivery, obstetric”[All Fields]) OR (“parturition”[MeSH
Terms] OR “parturition”[All Fields] OR “delivery, obstetric”[MeSH Terms]
OR (“delivery”[All Fields] AND “obstetric”[All Fields]) OR “obstetric
delivery”[All Fields]) OR (“abortion, spontaneous”[MeSH Terms] OR
(“abortion”[All Fields] AND “spontaneous”[All Fields]) OR “spontaneous
abortion”[All Fields] OR (“abortion”[All Fields] AND “spontaneous”
[All Fields]) OR “abortion, spontaneous”[All Fields]) OR (“abortion,
induced”[MeSH Terms] OR (“abortion”[All Fields] AND “induced”
[All Fields]) OR “induced abortion”[All Fields] OR (“abortion“[All Fields]
AND “induced”[All Fields]) OR “abortion, induced”[All Fields]))
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design. Of these, three comprised data on outcomes in
pregnancy and birth, one had postpartum data only
(from 27 days to one year), and five comprised data on
all these three episodes (Table 3). There were no restric-
tions for age, parity, ethnicity or other variables. We
included papers written in the languages English,
German, French and Swedish, and had no restrictions
for age, parity, ethnicity or other variables.
The studies were published from year 2000 to 2015;
one each performed in Turkey [68], Sweden [69],
Australia [67], Taiwan [70], Canada [71] and Denmark
[72]; two in United Kingdom [73, 74], and one study
using data from an international data base of Lithium
treated persons including Austria, Canada, the Czech
Republic, Denmark, Germany and Sweden [75]. Four of
the publications were cohort studies, and five case
control studies where outcomes of pregnancy were com-
pared for women with BD and those without. The objec-
tives of the papers varied.
Definitions of bipolar disorder used in the papers var-
ied from BD (DSM-IV not specified), BD-I and BD-II
(DSM-IV), BD (ICD-10 codes F30-31, F34.0 and F38),
RDC [76], BD (ICD-9 codes 296.0 and 296.2-5), BD
(ICD-8 codes 296.19, 296.39 and 298.19), BD (ICD-9,
ICD-10CA not specified) and BD (ICD-9-CM codes
295.XX, 296.0X, 296.1X, 296.4X, 296.5X, 296.6X,
296.7X, 296.80 or 296.89). (Table 3) Authors’ definitions
have been used in this review.
Mood episodes (Table 4)
Mood episodes during pregnancy and post-partum in the
women with BD
Three studies reported results both on mood episodes
during pregnancy or the post-partum period. Akdeniz et
al. [68] showed that 32 % of the women with BD had at
least one mood episode during pregnancy or within the
first month after childbirth. Di Florio et al. [73] reported
that 49.8 % of the women with BD-I and 42.2 % of
women with BD-II had a mood episode in pregnancy or
the post-partum period. Women who had a mood epi-
sode during their 1st pregnancy were, according to
Akdeniz et al. [68], more likely to have another episode
postpartum (OR 9.6 (95 % CI, 1.00–91.96). Also, women
who had a mood episode in the 1st post-partum period
were more likely to have a mood episode in the 2nd
post-partum period (OR 3.6, 95 % CI, 0.25–50.33). Di
Florio et al. [73] reported that women with BD-II had a
higher incidence of any perinatal mood episode com-
pared with women with BD-I (BD-II 18.4 % and BD-I
8.6 %, (chi-square = 10.38, d.f. = 1, p < 0.002 (calculated
by review authors)) and that the mood episodes were
significantly more common during the first month post-
partum than during pregnancy (BD-I OR 44.5 95 % CI
26.90–76.00 and BD II OR 4.7 95 % CI 2.40–9.80). Grof
et al. [75] show that episodes occurred significantly more
often in the post-partum period than before and during
pregnancy.
Fig. 1 Study selection flow diagram
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Table 3 Characteristics of 9 included studies




Aim of study Study design Diagnostic tool Sample Pharmaceutic treatment Length of
follow-up
Country
Akdeniz 2003 [68] M To evaluate and emphasise




period during the course







72 women with BD (252
pregnancies and 160
childbirths) Analysed a
sub group: (n = 23): every
mood episode that began
during pregnancy and in
postpartum period
following birth at gestation
26 weeks+
Of women with post-
partum episodes (n = 26)
21 had received
psychotropic medication.









Bodén 2012 [69] S To investigate the risks of
adverse pregnancy and birth








A cohort of 332,137 women
2005–2009. Women with a
record of at least two BD
diagnoses (n = 874), 320
treated with mood stabiliser,
554 untreated, compared
with all other women
giving birth (n = 331,263)







Di Florio 2013 [73] M To investigate the occurrence
and timing of perinatal mood






1212 women (980 with









Di Florio 2014 [74] M To test the hypothesis that
risk of perinatal mood episodes





1212 women (934 with
BD-I (1404 births), 278 with
BD-II (424 births)







Grof 2000 [75] M To examine statistically the
clinical course of 28 women
with typical bipolar disorder,
type I, who became pregnant







(Spitzer et al. 1978))
28 women with BD (56
pregnancies) and no
Lithium prophylaxis; 33


















Jablensky 2005 [67] M To determine the frequency,
nature, and severity of 25
obstetric complic-ations in
women with affective disorders






763 women with BD, 1,301
pregnancies; 1,831 women
(3,129 pregnancies) with








Lee 2010 [70] S To investigate pregnancy
outcomes among women with
bipolar disorder, compared
with women with no history
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528,061 women with no



















Table 3 Characteristics of 9 included studies (Continued)
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depressive disorder (controls);










Munk-Olsen 2009 [72] S To compare mothers and
nonmothers to assess whether
childbirth increases the risk for
psych-iatric readmission and
to identify pre-dictors of
psychiatric readmission during










All women born in Denmark
between Jan 1, 1955 and
July 1, 1990 who were
alive on their 15th birthday
and who had at least 1
psychiatric admission during
the study period: January
1, 1973, through June
30, 2005. Analysis group





















Table 4 Mood episodes in pregnancy and early postpartum period for women with bipolar disorder
First author, year of publication Key findings: reported by authors Potential mechanisms suggested by authors Key recommendations made by authors
Mood episodes
Akdeniz 2003 [68] In 13.9 % (n = 10), the BD illness started in the
peripartum period.
Twenty-three (32 %) women with BD reported
at least one mood episode during pregnancy
or within the first month after childbirth.
Eleven mood episodes occurred in pregnancy
(11 out of 252 pregnancies (4.4 %)) and which
started between 2nd and 8th pregnancy months.
Mean duration of episode was 5.5 weeks (SD 3.8,
range 1–12).
Twenty-six mood episodes occurred in the first
month postnatal (26 out of 160 births (16.3 %)).
Mean duration of episode was 4.5 weeks (SD 4.9,
range 1–23.5).
Women who had a mood episode during their
1st pregnancy, were more likely to have another
episode postpartum (OR 9.6 (95 % CI, 1.002–
91.964)).
Women were more likely to have
a postpartum mood episode after the birth of the
first child. Women who had a mood episode in
the 1st post-partum period were more likely to
have a mood episode in the 2nd post-partum
period (OR 3.6 (95 % CI, 0.257–50.330)).
Biological factors such as onset of BD at an
early age, antenatal mood episode and
obstetric complications appeared to influence
the risk, but psychosocial factors did not.
Need rigorous prospective studies. Avoid
discontinuing lithium treatment too abruptly.
Di Florio 2013 [73] Perinatal
episodes across the mood disorder
spectrum
Women with BD-I: 49.8 % had a mood episode in
pregnancy or the post-partum period (pregnancy
8.6 %, postpartum period within 12 months of
childbirth 91.4 %). More than 20 % were affected by
mania or psychotic depression in the pregnancy or
the post-partum period. 25 % had an episode of
non-psychotic depression.
Women with BD-II: 42.2 % had a mood
episode in pregnancy or the post-partum period
(pregnancy 18.4 %, postpartum period within 12
months of childbirth 81.6 %). Women with BD-II had
a higher incidence of any perinatal mood episode
compared with women with BD-I (chi-square = 10.38,
d.f. = 1, p < 0.002 (calculated by review authors).
The mood episodes were significantly more common
during the first month post-partum than during
pregnancy (BD-I OR 44.5 95 % CI 26.9–76.0 and BD II
OR 4.7 95 % CI 2.4–9.8).
Only most severe episodes were rated, so
other less severe disturbances may not have
been recorded; rates of BD recurrence in
pregnancy may thus be artificially low.
Prospective longitudinal studies are needed.
Women with BD should be informed of the
risk of peri-natal BD episode.
Di Florio 2014 [74] Mood disorders and
parity
Women with BD-I: 35 % reported an episode
(mania/ psychotic depression) in the first pregnancy,
20.5 % in second pregnancy and 14.6 % in
subsequent pregnancies. Rates of depression were
similar across all pregnancies and postpartum periods.
Women having their first baby are more
anxious and stressed, due to lack of experience.
Multiparous women with BD may be more
aware of the possibility of postnatal episodes,
and may start treatment prophylactically.
Clinical studies on the effect of parity on
mood disorders should also investigate
possible effect of medication reducing the













Table 4 Mood episodes in pregnancy and early postpartum period for women with bipolar disorder (Continued)
Women with BD-II: Rates of depression: first pregnancy
46 % and second pregnancy 33 %.
A significant association between parity and mood
episodes within 6 weeks postpartum was found.
There was no significant association between parity
and mood episodes in pregnancy or later postpartum.
Grof 2000 [75] Five out of 28 women had a relapse during pregnancy
(18 %), all in the last five weeks of pregnancy. Seven
(25 %) had a postpartum relapse: 1 to 5 times, lasting
3.5 months in average, 42 % of these were manic.
Postpartum episodes were significantly more than the
other two periods (before and during pregnancy).
Pregnancy seemed to confer a protective effect. In
pregnancy, the mean rate of recurrence was 0.14,
whereas mean rate in the 9 months prior to pregnancy
was 0.43 (p < 0.05). Duration was also less (mean of 0.9
weeks during pregnancy, compared with mean of 6.1
weeks before pregnancy, p < 0.01). Duration postpartum
was mean 12.2 weeks compared
to mean 0.9 in pregnancy, p < 0.001.
May be due to placental hormones increasing
throughout pregnancy, and abrupt cessation
after birth.
Stop psychotropic medication in pregnancy,
but continue to monitor women. Maybe
recommence medication in the last 6 weeks
of pregnancy.
Mei-Dan 2015 [71] 3.6 % (n = 66) of BD were hospitalised for psychiatric
reasons during the index pregnancy. (this is more than
for the major depressive disorder group: 1.9 % (n = 69)
Women with BD need more social support
Munk-Olsen 2009 [72] Women with previous diagnoses of BD, had the highest
risk of readmission 10 to 19 days postpartum (RR, 37.22;
95 % CI, 13.58–102.04) compared with mothers with BD
who gave birth 6 to 11 months earlier. Cumulative
incidence of admission 0–3 months postpartum was
22 %. During the first postpartum year, 26.9 % of all
women with BD predating childbirth were admitted.
May be due to decrease of hormones post
birth. Pregnancy, a time of emotional well-
being, provides protection from BD.
Women with BD who are pregnant or
considering pregnancy need careful
monitoring and relevant psychoeducation.













Mood episodes during pregnancy
Occurrence of mood episode during pregnancy was re-
ported in four studies. In a study by Grof et al. [75] 18 %
(five out of 28 women) had a relapse during pregnancy,
all in the last five weeks of pregnancy. Combining the
results of Akdeniz et al. [68] and Di Florio et al. [73] (as
both studies used the DSM-IV definition) gives an over-
all prevalence for a mood episode during pregnancy of
9.3 % (104 women out of 1116).
Di Florio et al. [74] found that 35 % of the women with
BD-I reported an episode (mania/psychotic depression) in
the first pregnancy, 20.5 % in second pregnancy and
14.6 % in subsequent pregnancies. For women with BD-II
the rates of depression in first pregnancy were 46 % and
second pregnancy 33 %. Rates of depression were similar
across all pregnancies and postpartum periods.
Mood episodes post-partum
Occurrence of mood episodes in the post-partum period
was reported in four studies. In the study by Grof et al.
[75], 25 % (seven out of 28) of the women had a postpar-
tum relapse from 1 to 5 times, lasting 3.5 months on
average; 42 % of these were manic. Combining the re-
sults of Akdeniz et al. [68] and Di Florio et al. [73] for
mood episodes post-partum shows a prevalence of
79.2 % (812 out of 1024 births).
There was no significant association between parity
and mood episodes in pregnancy or later post-partum
according to Di Florio [74]. However, a significant asso-
ciation between parity and mood episodes within 6 weeks
postpartum was found, with primiparous women being
more likely to experience an episode.
Admission during pregnancy
Mei-Dan et al. [71] reported that 3.6 % (n = 66) of the
women with BD were hospitalised for psychiatric rea-
sons during pregnancy. This is more than for women
with major depressive disorder, where 1.9 % (n = 69)
were admitted during pregnancy. Risk calculations for
admission during pregnancy were not reported.
Readmission post-partum
Munk-Olsen et al. [72] showed in a register-based co-
hort study (study period 1973–2005) that 26.9 % of all
Danish women with BD with previous psychiatric admis-
sion(s) before birth of their first child were readmitted
during the first year post-partum. That is almost twice
as high compared to women with schizophrenia-like dis-
orders (15.7 %). The highest risk of readmission was 10
to 19 days postpartum (RR, 37.22; 95 % CI, 13.58–
102.04) compared with mothers with the same diagnoses
who gave birth 6 to 11 months earlier. The cumula-
tive incidence of admission 0 to 3 months postpartum
was 22 %.
Pregnancy and childbirth related issues and
complications (Table 5)
Non spontaneous (artificial) start of childbirth (induction or
planned caesarean section)
One retrospective cohort study [69] found that women
without BD had a rate of induction of labour of 20.7 %;
in women with BD without treatment it was 30.9 %,
Adjusted Odds Ratio (AOR) 1.57 (95 % CI 1.30 to 1.90);
in women with BD with treatment it was 37.5 %, AOR
2.12 (95 % CI 1.68 to 2.67). Women without BD had a
rate of caesarean birth of 16.8 %; in women with BD
without treatment it was 23.5 %, AOR 1.45 (95 % CI
1.18 to 1.78); in women with BD with treatment the rate
of caesarean birth was 25.6 %, AOR 1.56 (95 % CI 1.20
to 2.03) [69].
Gestational diabetes
One Swedish register study examined the relationship
between BD and gestational diabetes. The analysis did
not find any increased risk for gestational diabetes in
either pharmaceutical-treated (OR 1.18 (95 % CI 0.55–
2.56)) or untreated women with BD, compared with
those without (OR 1.06 (95 % CI 0.56–2.02)) [69].
Gestational hypertension
One population-based national study in Taiwan found
that women with BD were more likely to have gesta-
tional hypertension than pregnant women with no his-
tory of mental health difficulties. The odds ratio (AOR)
was 2.81 when adjusted for maternal age, education
level, marital status, infant gender, parity, family months
income, parental age difference and parental education
level (95 % CI 2.53–3.10) [70].
Antepartum hemorrhage
One cohort study showed that women with BD in
Australia were more likely to have antepartum haemor-
rhage than pregnant women with no history of mental
health difficulties (unadjusted OR 1.66 (95 % CI 1.15–
2.39)). When adjusting for maternal age, parity, plurality,
marital status, originality, and sex, the increased risk of
obstetric complications remained (AOR 1.60, 95 % CI =
1.11–2.32). However, those who developed BD after the
index birth were at no more risk during pregnancy and
birth than the women without mental health difficulties
(OR 1.02, 95 % CI = 0.92–1.12) [67].
Placenta praevia
One cohort study showed that women with BD were
more likely to have placenta praevia than pregnant
women with no history of mental health difficulties (OR
2.04 95 % CI 1.11–3.73). After adjustment for maternal
age, parity, plurality, marital status aboriginality and sex
the risk remained (AOR 2.13; 95 % CI 1.15–3.94) [67].
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Table 5 Obstetric complications in women with bipolar disorder
First author, year of
publication





Jablensky 2005 [67] Women with pre-existing BD had a significantly
increased risk of obstetric complications (OR 1.13,
95 % CI = 1.02–1.25), whereas those who developed
BD after the index birth were at no more risk than
the women without mental health difficulties
(OR 1.02, 95 % CI = 0.92–1.12) (Chi-square =157.56,
df = 8, p < 0.0001).
Antepartum hemorrhage
Jablensky 2005 [67] Women with BD were more likely to have
antepartum haemorrhage than pregnant
women with no history of mental health difficulties
(adjusted OR 1.60 (95 % CI 1.11–2.32)).
Possibly due more to clustering of
adverse maternal characteristics





Jablensky 2005 [67] Women with BD were more likely to have placenta
praevia than pregnant women with no history of
mental health difficulties (adjusted OR 2.13 (95 % CI
1.15–3.94)).
Women with pre-existing BD had a significantly
increased risk of obstetric complications (OR 1.13,
95 % CI = 1.02–1.25), whereas those who developed
BD after the index birth were at no more risk than
the women without mental health difficulties
(OR 1.02, 95 % CI = 0.92–1.12) (Chi-square =157.56,
df = 8, p < 0.0001).
Possibly due more to clustering of
adverse maternal characteristics than





Lee 2010 [70] Women with BD were more likely to have gestational
hypertension (1.5 % vs. 0.5 %) than pregnant women
with no history of mental health difficulties (p < 0.02).
None None
Gestational diabetes
Lee 2010 [70] No difference in rates of gestational diabetes between
women with and without BD.
None None
Bodén 2012 [69] No increased risk for gestational diabetes in either
treated or untreated women with BD compared to
women without BD.
Induction/elective CS
Bodén 2012 [69] Instrumental birth: Women without BD 24.7 %; BD
without treatment 33.0 %, AOR 1.49 (95 % CI 1.24 to
1.81); BD with treatment 34.1 %, AOR 1.39 (95 % CI
1.09 to 1.79)
Caesarean birth: Women without BD 16.8 %; BD without
treatment 23.5 %, AOR 1.45 (95 % CI 1.18 to 1.78); BD with
treatment 25.6 %, AOR 1.56 (95 % CI 1.20 to 2.03)
Non-spontaneous start of labour: Women
without BD 20.7 %; BD without treatment 30.9 %,
AOR 1.57 (95 % CI 1.30 to 1.90); BD with treatment
37.5 %, AOR 2.12 (95 % CI 1.68 to 2.67)
Mood stabilising treatment is
not necessarily the sole reason
for increased risk of adverse
outcomes.
Important to balance risks
between treating and not
treating BD.
Preterm birth
Bodén 2012 [69] The risk of preterm birth (before 37 weeks gestation)
was increased for women with BD, both for the treated
and the untreated, compared with women without BD.
Women without BD 4.8 %; BD without treatment 7.6 %,
AOR 1.48 (95 % CI 1.08 to 2.03); BD with treatment 8.1 %,
AOR 1.50 (95 % CI 1.01 to 2.24).
None None
Lee 2010 [70] Women with BD were more likely to have preterm
births (14.2 % vs 6.9 %) than pregnant women with
no history of mental health difficulties (AOR 2.08
(95 % CI 1.53–2.83).
Smoking could be a large part
of the causation
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Preterm birth (before 37 weeks gestation)
Three studies examined this issue and found a combined
prevalence of 10.68 % for preterm birth (PTB) in women
with BD (328 out of 3070), compared with a rate of
6.12 % in women with no mental health problems
(79,030 out of 1,291,682). This was a statistically signifi-
cant difference (Z = 10.37, p < 0.0001, OR 1.83, 95 % CI
1.64 to 2.06).
Bodén et al. [69] found that the risk of PTB was in-
creased for women with BD compared with women
without BD (4.80 %), both for those treated (8.10 %,
AOR 1.50, 95 % CI 1.01 to 2.24) and untreated (7.60 %,
AOR 1.48, 95 % CI 1.08 to 2.03), when adjusted for birth
order, maternal age, cohabitation, smoking, height, alco-
holism and substance misuse. Lee and Lin [70] similarly
showed that women with BD were more likely to have
PTB (14.20 % vs 6.90 %) than women with no history of
mental health difficulties (AOR 2.08, 95 % CI 1.53–2.83),
when adjusted for maternal age, education level, marital
status, infant gender, parity, family months income,
parental age difference and parental education level.
Mei-Dan et al. [71] also found a higher prevalence of
PTB for women with BD (11.40 %), (AOR 1.95, 95 % CI
1.68–2.26) compared with the control group (6.20 %),
when adjusted for maternal age, parity, obesity, sub-
stance abuse and medical and obstetric complications.
Early preterm occurrence was studied in the Canadian
study. Preterm birth defined as < 32 gestational weeks
was increased: 9.1 % vs 1.1 %. AOR: 1.70 (95 % CI 1.16–
2.48). Preterm birth defined as < 28 gestational weeks
show no significant increased risk: BD 0.9 % vs 0.6 % in
the referent group (AOR 1.66; 95 % CI 0.92–3.02) [71].
Mode of birth
Mode of birth was reported in one study, the Swedish
cohort. Compared to women without BD emergency
caesarean section was about 50 % increased in women
with BD. Adjustment was done for birth order, maternal
age, cohabitation, smoking, height, alcoholism and sub-
stance misuse. For untreated women the AOR was 1.45
(95 % CI 1.18 to 1.78), and in treated women it was 1.56
(95 % CI 1.20–2.03). Similar results were found for vagi-
nal instrumental birth (vacuum extraction or forceps):
AOR in untreated BD was 1.49 (95 % CI 1.18–1.78), and
treated BD women AOR 1.39 (95 % CI 1.20–2.03) [69].
Fetal and neonatal outcomes (Table 6)
Congenital anomalies
Congenital abnormalities (CA) were examined in three
studies. Jablensky et al. [67] found no difference in con-
genital abnormalities in women with BD (n = 62 out of
1,301, 4.80 %) compared with those with no mental
health difficulties (n = 152 out of 3,129, 4.90 %), but is
not included in the meta-analysis.
The combined results of the other two studies [69, 71]
showed that 21,632 women without BD had a baby with
congenital abnormality, out of 766,750 (2.82 %), while
175 women with BD, out of 4034, had one (4.34 %). This
difference is statistically significant (chi-square = 33.59,
p < 0.0001, OR 1.56, 95 % CI 1.34 to 1.82). There was no
heterogeneity shown between the two studies: Chi2 =
0.02, df = 1 (P = 0.90); I2 = 0 %.
Mei-Dan et al. [71] found that BD presented increased
risk for congenital anomalies (n = 90 out of 1859,
5.00 %) compared with the referent group (n = 14,963
out of 432,358, 3.50 %), when adjusted for maternal age
and parity (AOR 1.48, 95 % CI 1.20–1.82). Bodén et al.
[69] also found the prevalence of congenital malforma-
tions was 2 % for infants born to women without BD
(i.e., the normal population). For women with BD who
were not treated with mood stabilisers the rate was
1.90 %, and those women with BD who were treated
with mood stabilisers had rates ranging from 0 to
3.50 %, depending on the drug used. The authors did
not compare these results statistically; however, if the re-
sults for women without BD and the women with no
Table 5 Obstetric complications in women with bipolar disorder (Continued)
Mei-Dan 2015 [71] Preterm birth was defined as < 37 gestational weeks.
Higher prevalence for BD women 11.4 %, 212 out of
1858) and the BD group together with the ‘major
depressive disorder’ group with preterm birth (11.4 %,
N = 405) did, together, show increased prevalence above
the referent group (6.2 %, n = 27000). Crude OR for BD:
1.93 (95 % CI 1.67–2.23. Adjusted OR for BD: 1.95 (1.68–
2.26) when the control group was the referent (=1.00),
adjusted for: maternal age, income quintile, hypertension,
venous thromboembolic disease, gestational diabetes
mellitus, gestational hypertension, preeclampsia/
eclampsia. Preterm birth defined as < 32 gestational
weeks. BD did have increased risk. N = 34, 9.1 %. Referent
group n = 4884, 1.1 %. AOR: 1.70 (95 % CI 1.16–2.48).
Preterm birth defined as < 28 gestational weeks. No
significant increased risk.
None None
BD Bipolar Disorder, CI Confidence Interval, AOR Adjusted Odds Ratio, OR Odds Ratio
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Table 6 Fetal and neonatal complications in babies of women with bipolar disorder
First author, year of
publication





Jablensky 2005 [67] Defined as < percentage estimated birth weight
< 10th percentile. Women with BD were NOT
more likely to have LBW infants (9.9 % vs.9.3 %)
than pregnant women with no history of mental
health difficulties.
This cohort included only 55 % of women with
pre-existing BD, who had a significantly increased
risk of obstetric complications (OR 1.13, 95 % CI =
1.02–1.25), whereas those who developed BD
after the index birth were at no more risk than
the women without mental health difficulties
(OR 1.02, 95 % CI = 0.92–1.12) (Chi-square =157.56,
df = 8, p < 0.0001).
None None
Lee 2010 [70] Women with BD were more likely to have low
birth weight infants (9.8 % vs.5.7 %) than pregnant
women with no history of mental health difficulties
(AOR 1.66 (95 % CI 1.16–2.38)).
Smoking could be a large
part of the causation




Bodén 2012 [69] No significant results for SGA were reported for
women with BD (neither for the group treated with
mood stabilisers nor for those not treated).
None None
Jablensky 2005 [67] No difference found in SGA in women with BD
compared with those with no mental health difficulties.
None None
Lee 2010 [70] Women with BD were more likely to have SGA
(22.3 % vs.15.7 %) than pregnant women with no
history of mental health difficulties (AOR 1.47 (95 %
CI 1.14–1.91)).
Smoking could be a large
part of the causation
Monitoring of fetus, early
intervention if required.
Mei-Dan 2015 [71] Severe SGA (<3rd percentile), was not significantly
elevated in BD (n = 84, 4.6 %; AOR 1.15 (95 % CI 1.05–1.42)
compared with the referent group (n = 16.823, 3.9 %).
SGA (<10th percentile): BD presented increased risk
compared to reference group: BD: n = 258 of 1859 14.1 %,
reference group n = 54 858 12.8 %. AOR 1.17 (95%CI 1.03–1.34).
Adjusted for: maternal age, income quintile, hypertension,
venous thromboembolic disease, gestational diabetes,
gestational hypertension, pre-eclampsia/eclampsia
None Interventions should be
evaluated, to optimise health
of women with BD
LGA
Mei-Dan 2015 [71] Severe LGA (>97th percentile) was significantly more
common among women with BD (n = 69, 3.8 %; AOR
1.29. 95 % CI 1.08–1.54). Reference group 2.7 %, n = 11 712.
Adjusted for: maternal age, income quintile, hypertension,
venous thromboembolic disease, and gestational diabetes,
gestational hypertension, pre-eclampsia/eclampsia
LGA (>90th percentile) was NOT significantly more
common. BD 167 of 1859 9.1 % compared to referent
without mental illness n = 35,158 8.2 %. AOR 1.13 (0.96.1.32).
None Interventions should be
evaluated, to optimize health
of women with BD
Congenital anomalies
Bodén 2012 [69] Congenital malformations in infants born to women:
without BD: 2.0 %; with BD without treatment with mood
stabilisers: 1.9 %; with BD with treatment with mood
stabilisers: 0 to 3.5 %, depending on the drug used,
average 3.4 % (Numbers calculated by this review team).
None None
Jablensky 2005 [67] No difference found in congenital abnormalities in women
with BD compared with those with no mental health
difficulties.
None None
Mei-Dan 2015 [71] BD did present increased risk for congenital anomalies.
BD n = 90, 0.5 %. Referent group n = 14 963, 3.5 %. AOR:
1.48 (95 % CI 1.20–1.82) Adjusted for: maternal age, income
quintile, hypertension, venous thromboembolic disease,
None None
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Table 6 Fetal and neonatal complications in babies of women with bipolar disorder (Continued)
gestational diabetes, gestational hypertension,
pre-eclampsia/eclampsia
Neonatal re-admissions
Mei-Dan 2015 [71] Neonatal admission, < 28 days of life. BD did have
increased risk. N = 36, 2.0 % compared to referent n = 3953,
0.9 %. AOR: 2.41 (95 % CI 1.76–3.31) Adjusted for:
maternal age, income quintile, hypertension, venous




Jablensky 2005 [67] No difference in fetal distress, cephalopelvic disproportion,
atypical presentation, or cord anomalies, threatened
preterm labor, early rupture of the membranes, prolonged
labour, low 5-min Apgar scores, neonatal mortality in
women with BD compared with those with no mental
health difficulties.
None None
Boden 2012 [69] Showed no difference in low Apgar scores between
women without BD and those untreated (AOR 1.56, 95 %




Jablensky 2005 [67] No difference found in stillbirths in women with BD
compared with those with no mental health difficulties.
None None
Mei-Dan 2015 [71] BD did not present increased risk for stillbirth. BD n = 11,
0.6 %. Referent group n = 2235, 0.5 %. AOR 1.20 (95 5 CI
0.66–2.18), adjusted for: maternal age, income quintile,
hypertension, gestational diabetes, gestational hypertension,
venous thromboembolic disease, preeclampsia
None None
Infant mortality
Mei-Dan 2015 [71] Infant mortality < 28 days of life. BD did not have increased
or reduced risk N =≤ 5, referent group n = 1004, 0.2 %. AOR:
0.72 (0.23–2.23). Mortality <1 year of life. No difference in risk
BD n = 7, 0.4 % referent group n = 1389, 0.3 %. AOR: 0.99
(95 % CI 0.44–2.22)
None None
Neonatal morbidity
Mei-Dan 2015 [71] Secondary outcome; neonatal morbidity defined as RDS
(respiratory distress syndrome), Seizure, sepsis, IVH
(Intravenous hyperalimentation), persistent fetal circulation,
and neonatal abstinence syndrome.
1. Any of these neonatal morbidities: BD had increased risk:
n = 96, 5.4 %. Referent group (without mental illness)
n = 8270, 1.9 %. AOR 2.99 (95 % CI 2.44–3.66)
2. RDS: BD had increased risk. N = 26, 1.5 %. Referent group:
n = 4049, 1.0 %. AOR 1.64 (95 % CI 1.13–2.39)
3. Seizure: BD had increased risk. BD n = 10. 0.6 %, referent
group n = 844, 0.2 %. AOR = 2.54 (95%CI 1.31–4.90).
4. Sepsis: BD had increased risk. BD n = 23, 1.3 %, referent
group 3178, 0.7 %. AOR: 1.80 (95 % CI 1.20–2.70)
5. IVH: BD had increased risk. BD n = 13, 0.7 %. Referent
group n = 1485, 0.3 %. AOR: 2.12 (95 % CI 1.22–3.67).
6. Persistent fetal circulation. BD did NOT have increased
risk. BD n =≤ 5, referent group n = 615, 0.1 %. AOR: 1.89
(95 % CI 0.78–4.58).
7. Neonatal abstinent syndrome. BD had severe increased risk.
BD n = 70, 1.9 %. Referent group n = 177, 0.0 %. AOR = 52.2
(95 % CI 36.5–74.7)
Adjusted for: maternal age, income quintile, hypertension,
venous thromboembolic disease, gestational diabetes,
gestational hypertension, pre-eclampsia/eclampsia
None None
BD Bipolar Disorder, CI Confidence Interval, SGA Small for Gestational Age, LGA Large for Gestational Age, AOR Adjusted Odds Ratio, OR Odds Ratio
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treatment for BD are combined (6528 abnormalities out
of 331,817, 2.00 %) and compared with the 12 abnormal-
ities out of 320 women with BD who were treated
(3.75 %), the difference is statistically significant (Z =
2.19, p < 0.03, OR 1.91, 95 % CI 1.07–3.39), indicating
that medications for the treatment of BD in pregnancy
are associated with fetal abnormalities.
Small for gestational age (SGA)
Findings were mixed in the four studies examining this
outcome, and definitions differed. Boden et al. [69] used
≤2nd-3rd centile (severe SGA) and Mei-Dan et al. [71]
used <3rd centile (severe SGA), while Jablensky et al.
[67], Lee and Lin [70] and Mei-Dan et al’s [71] second-
ary outcomes used <10th centile. No significant results
for severe SGA were reported for women with BD in
Mei-Dan et al. [71] (4.6 % versus 3.9 %), or in Bodén et
al’s study [69] (3.33 % versus 2.30 %), neither for the
group treated with mood stabilisers nor for those not
treated. However, combining results from the two
studies gives prevalence rates of 4.14 % for women
with BD (113 out of 2729), compared with 3.20 % for
those without (24,418 out of 762,619), a statistically
significant difference (Z = 2.79, p < 0.006, OR 1.31,
95 % CI 1.08 to 1.58).
Results from the three studies that used the <10th
centile definition differed. Jablensky et al. [67] found no
difference in women with BD compared with those with
no mental health difficulties, but was not included in the
meta-analysis.
Women with BD in Lee and Lin’s research [70] were
more likely to have SGA (22.3 % vs.15.7 %) than those
with no history of mental health difficulties (OR 1.47,
95 % CI 1.14–1.91). Mei-Dan et al. [71], in testing their
secondary outcome of SGA using the <10th centile def-
inition, found that women with BD had an increased risk
of SGA compared to the reference group, 13.9 % com-
pared to 12.7 %, AOR 1.17, 95 % CI 1.03–1.34, when
adjusted for maternal age and parity. When results from
these last two studies are combined (15.2 % versus
14.3 %), there is no significant difference using
unadjusted odds ratio (Z = 1.19, p = 0.24, OR 1.07, 95 %
CI 0.96 to 1.21). It would thus appear that women with
BD are more likely to have babies with severe SGA
(<2nd-3rd centile) but not SGA (<10th centile).
Large for gestational age fetus (LGA)
In Mei-Dan et al.’s [71] study, severe LGA, defined as
>97th centile, was significantly more common among
women with BD (3.8 %), AOR 1.29, 95 % CI 1.08–1.54,
compared to women with no mental difficulties (2.7 %),
when adjusted for maternal age and parity. However,
when LGA was defined as >90th centile, no difference
was seen between the rates for women with BD (9.10 %)
compared to women without mental illness (8.2 %),
AOR 1.13 95 % CI 0.96–1.32.
Low birthweight
Two studies measured low birthweight (LBW), defined
as the birth weight <10th centile [67] or <2,500 g [70].
In Jablensky et al’s [67] study women with BD were not
more likely to have LBW infants (9.9 % vs.9.3 %, OR
1.06 95 % CI 0.82–1.36) than pregnant women with no
history of mental health difficulties. Women with BD in
Lee and Lin’s study [70] were more likely to have LBW
infants (9.8 % vs.5.7 %) than pregnant women with no
history of mental health difficulties (OR 1.66, 95 % CI
1.16–2.38).
Fetal distress/low Apgar score
Jablensky et al. [67] found no difference in fetal distress
or low 5-min Apgar scores in women with BD compared
to those with no mental health difficulties. Boden et al.
[69] also showed no difference in low Apgar scores be-
tween women without BD and those untreated (AOR
1.56, 95 % CI = 0.85–2.86) and treated (AOR 0.88, 95 %
CI = 0.33–2.34) for BD in pregnancy.
Stillbirth
Neither Jablensky et al. [67] nor Mei-Dan et al. [71]
found any difference in the rate of stillbirths in women
with BD compared with those with no mental health
difficulties.
Neonatal readmissions
Mei-Dan et al. [71] studied neonatal admission up to
28 days of life. Babies of women with BD did have an in-
creased risk (2.0 %) compared to those of women with
no mental health difficulties (0.9 %) AOR 2.41, 95 % CI
1.76–3.31, when adjusted for maternal age and parity.
Infant mortality
Infant mortality defined as death before the 28th day of
life was studied by Mei-Dan et al. [71]. The risk for
women with BD was the same as that for women with
no mental health problems (0.2 %) AOR 0.72, 95 % CI
0.23–2.23.
Neonatal morbidity
Neonatal morbidity, studied by Mei-Dan et al. [71] only,
was defined as RDS (respiratory distress syndrome), seiz-
ure, sepsis, IVH (intravenous hyperalimentation), persist-
ent fetal circulation, and neonatal abstinence syndrome.
The risk of having any of these neonatal morbidities was
higher in women with BD (5.4 %) compared with those
without mental illness (1.9 %) AOR 2.99, 95 % CI 2.44–
3.66. When analysed separately, babies of women with
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BD had higher rates for RDS, seizure, sepsis, IVH and
neonatal abstinence syndrome. No difference was seen
between the two groups of women in persistent fetal
circulation (AOR 1.89, 95 % CI 0.78–4.58).
Discussion
This systematic review has presented the wide-ranging
health outcomes for women with bipolar disorder and
their fetuses/babies. Mental health risks to women in-
clude the occurrence of mood episodes during preg-
nancy, rates of which varied across the studies from 9 to
18 %. Mood episodes were more common in the post-
partum period [73, 75], ranging from 25 to 79 %, with
differences possibly due to small sample sizes in some
studies [36, 44]. It has been suggested that this may be
due to placental hormones increasing throughout preg-
nancy, and their abrupt cessation after birth [75]. In
addition, mood episodes were found to be more com-
mon in first pregnancies [73]. Similar results were found
in a recent meta-analysis [54]; this review differs in
methodology from ours as it included women who had a
psychotic or manic episode following childbirth, even if
they had never had a diagnosis of BD in pregnancy.
It also included papers that compared different medi-
cation regimes, or stopping treatment at different
times, which we chose to exclude as there are so
many different treatments. Perhaps because of this,
our postpartum relapse rate (79 %) was much higher
than that quoted by Wesseloo et al. [54].
Single studies showed some incidence of increased
risks in pregnancy; induction of labour occurred in
women with BD, both treated and untreated, with rates
of 31 and 38 % respectively, compared with 21 % in
women without BD. Caesarean section rates were simi-
larly increased. Women with BD were also more likely
to have gestational hypertension [70], antepartum haem-
orrhage and placenta praevia [67]. Emergency caesarean
section was about 50 % increased in women with BD,
and similar results were found for vaginal instrumental
birth [69]. There was no increased risk of gestational
diabetes found [69, 70]. Pre-term birth showed a differ-
ence (10.68 % versus 6.12 %, two studies, total popula-
tion 1,294,752). Lee and Lin [70] believed that smoking
could be a large part of the causation, as in their (and
other) studies women with BD had a higher prevalence
of smoking behaviour.
Babies of women with BD have a higher prevalence of
congenital abnormalities (4.34 % versus 2.82 %, two
studies, total population 770,784), although the three pa-
pers examined differed in their individual findings. The
difference is likely due to the smaller sample size in
Jablensky’s work [67], at just over 6,000, and to the fact
that this cohort included only 55 % of women with pre-
existing BD. Other factors include the separation of
women treated and un-treated for BD in Boden’s study
[69], and the fact that Mei-Dan’s study population [71]
were women previously hospitalised for bipolar disorder,
so it is likely that they were on medication for their BD
symptoms. There are many studies showing that mood
stabilisers do cause congenital abnormalities, and that
was not the focus of this review. It would appear from
the three papers summarised here that women with BD
who are not being treated with mood stabilisers in preg-
nancy might not be at the same level of increased risk of
congenital abnormalities. Lee and Lin [70] recom-
mended active monitoring of the fetus in pregnancy, and
early intervention if abnormalities are noted.
A new result demonstrated by the meta-analysis in this
review was that severe SGA (<2nd-3rd centile) was in-
creased in women with BD (4.14 % versus 3.20 %, two
studies, total population 765,348), in addition to previ-
ously reported increases in SGA based on the <10th cen-
tile definition [70, 71]. Again, smoking behaviour may be
the main cause, as suggested by both Lee and Lin [70]
and Jablensky et al. [67].
Large for gestational age babies, low birthweight, fetal
distress, low Apgar score, still-birth, neonatal readmis-
sions, infant mortality and neonatal morbidity were all
examined by individual studies only, or in two studies
that could not be merged for meta-analysis. Large for
gestational age babies defined as >97th centile, but not
as >90th centile, were more common in women with BD
[71], as were low birthweight babies [70], neonatal read-
missions [71] and any neonatal morbidity [71]. Fetal dis-
tress [67], low Apgar score [67, 69], still-birth [67, 71],
and infant mortality [71] showed no difference.
One paper published after the systematic review was
finished [51] showed that women with BD had lower
scores on maternal-infant interaction at 12 months post-
partum; this is an area that would benefit from further
study. Marengo et al. [52], also published after the sys-
tematic review was finished, highlighted results related
to reproduction decisions of women with BD. They
showed that women with BD had more unplanned preg-
nancies (37.7 % versus 9.6 %) and fewer planned preg-
nancies (32.8 % versus 78.1 %) than women in the
control group. They also found that women with BD
more often than those without had electively interrupted
at least one pregnancy (42.4 % versus 13.5 %). These
findings indicate that the complex picture of problems
for women with BD, mentioned in the introduction,
need to be further explored.
Review strengths and limitations
This is the first review, to our knowledge, that systemat-
ically searched the literature and summarised the risks
associated with bipolar disorder for pregnant women
and their babies. A key strength is the sourcing of
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literature from all languages. The result is a concise, ex-
tensive review that includes outcomes for both mother
and baby, and spans both physical and mental health.
Given the heterogeneity of data, particularly the use of
differing definitions of bipolar disorder, and of some out-
comes, we were unable to perform a meta-analysis for
all outcomes.
Conclusions
A clear negative impact of bipolar disorder on mothers’
and their babies’ health has been shown. Adverse out-
comes such as gestational hypertension and antepartum
haemorrhage occur in pregnant women with bipolar dis-
order. They are also prone to increased rates of induc-
tion of labour and caesarean section, and have an
increased risk of mood disorders in the postnatal period.
The risk of fetuses developing severe growth retardation
(<2nd-3rd centile) is increased in women with BD, and
increased neonatal morbidity is also found. In addition,
bipolar disorder is linked to a higher incidence of con-
genital abnormalities (if woman are treated with mood
stabilisers) and neonatal readmissions. These negative
outcomes lead to longer duration of hospital stay and in-
crease the costs of care. Active monitoring of the fetus
in pregnancy, early intervention if abnormalities are
noted, encouragement to decrease smoking behaviour
and close support and monitoring of the mother’s mood
postpartum are all likely to bring benefits in terms of
improved future health and decreased monetary outlay.
As only nine papers were suitable for inclusion in this
review, and as some of the studies did not control for
confounding variables, or included differing populations,
further research is required. In particular, large cohort
studies examining fetal abnormality outcomes for
women with BD who are not on mood stabilisers in
pregnancy are required, as are studies on maternal-
infant interaction. More qualitative studies are also rec-
ommended regarding these women's perspectives of
pregnancy, childbirth and early motherhood. The com-
pilation of these outcomes should be used to guide more
informed and supportive care for women with bipolar
disorder who embark on pregnancy and motherhood.
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